Lifecore Biomedical Stock Today
| LFCR Stock | 7.41 0.09 1.20% |
Performance16 of 100
| Odds Of DistressLess than 45
|
Lifecore Biomedical is selling at 7.41 as of the 30th of November 2024; that is 1.2% down since the beginning of the trading day. The stock's lowest day price was 7.41. Lifecore Biomedical has 45 percent odds of going through some form of financial distress in the next two years but had a very solid returns during the last 90 days. Equity ratings for Lifecore Biomedical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of February 1996 | Category Healthcare | Classification Health Care |
Lifecore Biomedical is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 36.83 M outstanding shares of which 2.47 M shares are now shorted by private and institutional investors with about 14.38 trading days to cover. More on Lifecore Biomedical
Moving together with Lifecore Stock
| 0.83 | VTRS | Viatris | PairCorr |
| 0.83 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.85 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against Lifecore Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lifecore Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | James Hall | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lifecore Biomedical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lifecore Biomedical's financial leverage. It provides some insight into what part of Lifecore Biomedical's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lifecore Biomedical (LFCR) is traded on NASDAQ Exchange in USA. It is located in 3515 Lyman Boulevard, Chaska, MN, United States, 55318 and employs 524 people. Lifecore Biomedical is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 276.02 M. Lifecore Biomedical conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.83 M outstanding shares of which 2.47 M shares are now shorted by private and institutional investors with about 14.38 trading days to cover.
Lifecore Biomedical generates negative cash flow from operations
Check Lifecore Biomedical Probability Of Bankruptcy
Ownership AllocationLifecore Biomedical maintains a total of 36.83 Million outstanding shares. Over half of Lifecore Biomedical's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Lifecore Ownership Details
Lifecore Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 303.4 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 300.1 K | |
| Dcf Advisers, Llc | 2024-09-30 | 288.5 K | |
| Northern Trust Corp | 2024-09-30 | 193.5 K | |
| Boothbay Fund Management, Llc | 2024-09-30 | 187.1 K | |
| Tocqueville Asset Management L.p. | 2024-09-30 | 151.7 K | |
| Quinn Opportunity Partners Llc | 2024-09-30 | 127.9 K | |
| Gamco Investors, Inc. Et Al | 2024-09-30 | 87.5 K | |
| Qube Research & Technologies | 2024-06-30 | 81.5 K | |
| Wynnefield Capital Inc | 2024-09-30 | 4.9 M | |
| Legion Partners Asset Management, Llc | 2024-09-30 | 3 M |
Lifecore Biomedical Historical Income Statement
Lifecore Stock Against Markets
Lifecore Biomedical Corporate Management
| Darren Hieber | Senior Partnerships | Profile | |
| Matt Augustson | Senior Technology | Profile | |
| Aaron Perlitsh | Director Officer | Profile | |
| Kara Morley | Senior Resources | Profile | |
| Brikkelle Thompson | Senior Resources | Profile |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.